NOTCH1 and acute lymphoblastic leukemia: Although several mutations and chromosomal changes have been identified in most cases and the roles of many oncogenes have been studied, for example the activating mutations of notch receptor 1 (NOTCH1) [2], the γ-secretase inhibitors (GSIs) targeting NOTCH1 signaling have shown unsatisfactory therapeutic effect on T-ALL [3], suggesting that more studies are urgently needed.